AZD2389

Phase 2Small molecule

AstraZeneca

AZD2389 is one of 79 small molecule programs targeting Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FibrosisActive, not recruiting

Liver FibrosisRecruiting

CirrhosisActive, not recruiting

FibrosisPhase 1

Active, not recruiting

Liver FibrosisPhase 2

Recruiting

CirrhosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

9 2

AZD2389

AstraZeneca

Phase 2

8 3

Crestor

AstraZeneca

Preclinical

2 4

HEPCLUDEX

Gilead

Preclinical

1 5

Farxiga

AstraZeneca

Preclinical

1 6

Thalomid

Bristol-Myers Squibb

Preclinical

1 7

Revia

Teva

Preclinical

1 8

Cipro

Bayer

Preclinical

1 9

Dobutrex

Eli Lilly

Preclinical

1 10

Azulfidine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Liver Fibrosis

NCT07610837

Clinical

Trials by Indication[1]

Tics3 trials

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06974565·16 enrolled

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06138795·120 enrolled

A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06846528·16 enrolled

Liver Fibrosis3 trials

A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06750276·40 enrolled

A Phase 1, Open-label Positron Emission Tomography Trial to Assess Changes in Liver Uptake of [68Ga]Ga-FAPI-46 Following Oral Administration of Single Doses of AZD2389 to Patients With Advanced Liver Fibrosis (PECHORA).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07069725·7 enrolled

A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07610837·104 enrolled

Hepatic Impairment1 trial

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06812780·35 enrolled

Midazolam1 trial

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06973005·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for AZD2389. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD2389 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD2389. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD2389

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Tics3 trials

Liver Fibrosis3 trials

Hepatic Impairment1 trial

Midazolam1 trial

References

Drug Info

Quick Facts

Related News